 |
||||||||||||||||||
|
|
|
||||||||||||||||||||||
|
|
|
|
||||||||||||||||||||||||||||||||||
|
|
|
 |
 |
 |
 |
|
 |
|
||||||
|
|
|
||||||||||||||
|
2002 News + Events |
||||||||||||
Winners
of 2002 Helix Award Announced |
|||||||||||||
|
New York (February 21, 2002) – CV Therapeutics and Isis Pharmaceuticals were presented with the seventh Annual Helix Award at the Biotechnology Industry Organization’s CEO & Investor Conference 2002 held at the Waldorf Astoria Hotel in New York. Isis Pharmaceuticals received the award for the emerging company category, and CV Therapeutics was honored in the large-cap category.The Helix Award is the highest award of corporate excellence for the international biotechnology industry. The award is presented based on leadership in three distinct areas of scientific innovation, company growth and corporate citizenship. Past winners include OSI Pharmaceuticals, Inc., of Melville, N.Y.; Genentech, Inc., of South San Francisco, Calif.; The Collaborative Group of Stony Brook, N.Y.; Regeneron Pharmaceuticals, Inc., of Tarrytown, N.Y.; Biogen, Inc. of Cambridge, Mass.; and Immunex of Seattle, Wash. These companies have all exemplified the true spirit of corporate leadership in the biotechnology industry.
"Isis has had a tremendous year with the establishment of several pivotal collaborations with industry leaders, major advances in the clinic and accomplishments in our two divisions, GeneTrove and Ibis Therapeutics," said Stanley T. Crooke, M.D., Ph.D., chairman and CEO of Isis. "We are honored that the industry is recognizing the company's achievements and the work of the more than 400 people at Isis". "I am honored to receive this important award on behalf of my colleagues at CV Therapeutics. This recognition from our peers highlights the critical work that our scientists and clinicians accomplish every day," said Louis G. Lange, M.D., Ph.D., Chairman and CEO of CV Therapeutics. "Our company was founded over ten years ago with a single goal: to find better ways to help patients with cardiovascular disease – still the number one cause of death in the United States. 2001 was highlighted by the positive results from our second pivotal Phase III trial, CARISA, which was presented as a Late Breaking Clinical Trial at the American Heart Association." The Helix Award is presented by the Long Island Life Sciences Initiative (LILSI) and is jointly sponsored by BIO, Stony Brook University and The Center for Biotechnology. The Helix Award is open to public and private U.S. or foreign-based biotechnology companies. An independent panel of judges reviewed the 2002 submissions, and KPMG LLP, an international professional services firm tabulated the results. LILSI is a not-for-profit trade association created to address issues of strategic importance to the biotechnology, pharmaceutical, medical device and life science technology-based industries. LILSI advocates on behalf of public policy that will improve the Long Island region's business climate for life science companies and enhance the research and business infrastructure that is vital to their success. More information on LILSI can be found at www.lilsi.org. The Helix Award is the only award for outstanding corporate achievement
in the global biotechnology industry. It was Center for Biotechnology Helps Form Long Island Life Sciences Initiative The Center for Advanced Technology (CAT) in Medical Biotechnology at Stony Brook University played a key role during December 2001 in the formal establishment of the Long Island Life Sciences Initiative (LILSI), a not-for-profit organization that will focus the collective energies of the pharmaceutical, biotechnology, medical device, and life systems technology sectors on issues of strategic importance to the growth, prosperity, and ultimate success of the life sciences industry on Long Island. With approximately 300 life sciences companies in the region, it is estimated that Long Island represents a full one-third of these industries in New York State. Joseph Scaduto, Business Development Associate at the CAT who will also lead LILSI as part-time Executive Director states, "LILSI will help to organize and assemble the life sciences industry on Long Island, and the potential for economic development in the region is enormous." An important mechanism by which the CAT creates economic impact is through the establishment of infrastructure necessary to foster new areas of scientific investigation, enhance the region's competitive position in pursuit of federal funding, and generate intellectual property that holds potential for economic impact in New York State. The CAT has already been successful in fostering growth of the life sciences industry by serving as a founder of both the Long Island High Technology Incubator (LIHTI) and the New York Biotechnology Association (NYBA). Now as a founder of LILSI, the CAT hopes to contribute to an agenda focused on industry needs that will help cultivate a nurturing environment for business, as well as issues that will facilitate technology development and commercialization of academic research. Diane Fabel, Deputy Director at the CAT, emphasizes that "LILSI will work to attract local, state and federal resources to Long Island in order to help sustain the life sciences industry, creating a cluster of successful, high-growth companies." LILSI will also support and promote workforce development programs that help industry and academic institutions build relationships that will address the industry's current and anticipated workforce needs. "LILSI will serve as a vehicle for economic development
for the Long Island region," Mr. Scaduto asserts, "Long Island
has the technology, business resources, and infrastructure to maximize
its potential as an epicenter for the life sciences regionally, nationally
and globally." Annual Careers in the Bioscience Industry Seminar Series at Stony Brook University This is a must attend seminar series for all graduates in the life sciences, computing and engineering fields. This series aims to increase awareness of career opportunities in the bioscience industry and to promote an interactive environment for communication between industry and the graduate student population. View 2001-2002 Seminar Series Schedule Wednesday, February 27, 2002. 12:30
-1:30 pm To attend this free seminar, please register online. Join Mr.
Joseph Scaduto, Executive Director, Long Island Life Sciences Initiative
(LILSI) and Business Development Associate, Center for Biotechnology as
he discusses the transition from graduate school to a career in the bioscience
industry. He will provide a personal insight into his professional career
development as he outlines critical steps involved in gaining industry
experience through internships, creative networking techniques, diverse
and exciting career opportunities in industry and what a career in business
development entails. This is a must attend seminar for all life sciences
graduates who are serious about pursuing a career in the industry. Don't
miss this opportunity to meet and discuss the realities of working in
industry and the strategies for breaking into the bioscience industry.
Light refreshments will be served. Tuesday, March 12, 2002. 10 am - 12:30 pm To attend this outing, please register online. The Center for Biotechnology is pleased to organize a visit to Pall Corporation. Pall is the global leader in the highly sophisticated filtration, separation and purification industry. From drug discovery, through pre-clinical and clinical trials, to full-scale production, Pall Corporation offers innovative and effective solutions in filtration, separation and purification challenges. All graduate students in the life sciences are invited to take this opportunity to visit Pall's Port Washington facility. Space is limited. Program Driving instructions to Port Washington. This visit is limited to 20 students.Transportation will be provided.
All students requiring a ride to and from Port Washington will meet at
8:30 am (sharp), in front of the Administration Building. Wednesday, Mar 20, 2002. 5 - 7 pm This seminar series is organized by The Center for Biotechnology and the Department of Biomedical Engineering. It is presented in partnership with the Career Center. * Please check back for updated information on speakers. * Note the specific times and different locations for each seminar Directions
to the Alliance Room. Annual Bioscience
Careers Conference: Visions for the Future
The Annual Bioscience Careers Conference on January 17, 2002 was a huge success. More than 200 Masters students, PhDs and Post Doctoral Fellows from the life sciences attended the all day conference at the CUNY Graduate Center in New York City. Participants at the conference represented more than 25 research and academic institutions throughout New York State including NYU, Cornell, Rockefeller University, Memorial Sloan Kettering Cancer Center, Columbia, Mount Sinai School of Medicine, Albert Einstein College of Medicine, Cold Spring Harbor Laboratory, Rochester Institute of Technology, CUNY and Stony Brook University.
Distinguished speakers from the bioscience industry presented insightful and engaging presentations on diverse career opportunities in Corporate R&D, Business Development, Investment Banking, Venture Capital, Finance, Law, Marketing, Communications and Investor Relations. The closing plenary, "Visions for the Future" engaged the audience in a thought provoking exploration of the state of New York's bioscience industry and its implication for education and economic development. Participants at the conference had an opportunity to meet with bioscience companies to discuss potential career opportunities. Companies that exhibited included -
The Center for Biotechnology would like to thank Morgan & Finnegan LLP for their sponsorship of the Closing Plenary, "Visions for the Future".
For details on the Annual Bioscience Careers Conference, please click here. back to top |
|
  |
CV
Therapeutics and Isis Pharmaceuticals win highest award of honor in the
biotechnology industry
